Source link : https://www.newshealth.biz/health-news/upadacitinib-effective-long-term-for-ad-in-adolescents/
TOPLINE: Long-term treatment with upadacitinib in adolescents with moderate to severe atopic dermatitis (AD) demonstrated sustained efficacy and an acceptable safety profile through 76 weeks across three phase 3 trials. METHODOLOGY: Researchers conducted three double-blind, placebo-controlled phase 3 randomized clinical trials (Measure Up 1, Measure Up 2, and AD Up) involving 542 adolescents aged 12-17 […]
Author : News Health
Publish date : 2024-10-28 07:53:08
Copyright for syndicated content belongs to the linked Source.
